To examine whether previous severe hypoglycemic events were associated with the risk of all-cause mortality after major cardiovascular events (myocardial infarction [MI] or stroke) in patients with type 1 diabetes.
individual with type 1 diabetes experiences about two episodes of symptomatic hypoglycemia per week, with an annual prevalence of 30-40% for hypoglycemic episodes requiring assistance for recovery (2) . We define severe hypoglycemia to be an episode of hypoglycemia that requires hospitalization in this study.
The evidence surrounding the impact that severe hypoglycemia has on cardiovascular events and mortality in patients with diabetes is limited. In studies of type 2 diabetes, two trials found higher mortality in patients with severe hypoglycemia than those without hypoglycemia (3, 4) , while the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial showed that severe hypoglycemia was associated with a significant increase in the adjusted risks of major micro-and macrovascular events, cardiovascular death, and all-cause death (5) . Patients with type 1 diabetes are more susceptible to hypoglycemia than those with type 2 diabetes, and therefore it is potentially of greater relevance if severe hypoglycemia is associated with mortality (6) . In type 1 diabetes, the Diabetes Control and Complications Trial (DCCT) compared the effects of standard blood glucose control versus intensive control on the complications of diabetes (7) . The DCCT demonstrated a threefold increased risk for severe hypoglycemia in the intensive treatment group compared with the conventional group (6) . The low incidence of cardiovascular disease (CVD) events in the DCCT meant there was a lack of statistical power to investigate whether severe hypoglycemia was associated with mortality after major cardiovascular events (6) ; therefore, there is a need to explore this issue elsewhere.
We derive equations for all-cause mortality risk after a major cardiovascular complication in type 1 diabetes and use these to estimate 5-year cumulative mortality risk for people with particular characteristics. These estimates quantify how the impact of prior severe hypoglycemic events on mortality after a major cardiovascular complication compares with the impact of important clinical risk factors, such as, BMI, HbA 1c , and other comorbidities.
RESEARCH DESIGN AND METHODS

Data
This study uses a large linked data set comprising health records from the Swedish National Diabetes Register (NDR), which were linked to administrative records on hospitalization, prescriptions, and national death records. Initiated in 1996 as a tool for quality assurance in diabetes care, reporting to the NDR is not mandatory, but all hospital diabetes outpatient clinics and primary health care centers are encouraged to do so. All included patients have agreed to be registered before inclusion. Today, 100% of hospital outpatient clinics and 95% of primary health care centers participate. In Sweden, almost all patients with type 1 diabetes receive their treatment at hospital outpatient clinics, with an estimated 90% of adult patients with type 1 diabetes reporting to the NDR in 2011. Demographic data, diabetes duration, and treatment modalities, as well as various risk factors and diabetes complications, are recorded (7).
This study is based on data from four sources: 1) risk factor data from the Swedish NDR (1 January 1987-31  December The data were confidentially linked at the patient level by the NDR. The regional ethics committee at the University of Gothenburg approved the study. Inpatient episodes refer to all recorded admissions at Swedish hospitals for patients with type 1 diabetes registered with the NDR. The IPR was established in 1964, and diagnoses are coded according to the Swedish ICD system. A study comparing registered diagnoses in the IPR with information in medical records found positive predictive values of IPR diagnoses were 85-95% for most diagnoses (8) . In terms of NDR coverage, a recent study found that 91% of those aged 18-34 years and with type 1 diabetes in the Prescribed Drug Register could be matched with those in the NDR for 2007-2009 (9) .
The outcome of the study was allcause mortality after a major cardiovascular complication (MI or stroke). Our sample for analysis included patients with type 1 diabetes who visited a clinic after 2002 and experienced a major cardiovascular complication after this clinic visit. Only the next major cardiovascular complication recorded after their clinic visit was included. This may or may not have been the individuals' first major CVD event but was the next event that occurred after they entered the observation period. We define type 1 diabetes as diabetes diagnosed under the age of 30 years, being reported as being treated with insulin only at some clinic visit, and when alive, having had at least one prescription for insulin filled per year between 2006 and 2010 (the full calendar years for which prescription data were available), and not having filled a prescription for metformin at any point between July 2005 and December 2010 (under the assumption that metformin users were more likely to be type 2 diabetes patients).
A severe hypoglycemic event was defined as one that required hospitalization, identified through ICD hospitalization codes recorded in the Supplementary Data. Type 2 diabetes ICD codes were also included, as it was assumed these were reporting errors in the hospital admission codes and that these patients were actually patients with type 1 diabetes based on their NDR identification. Only the first and second hospitalization codes were used to identify events. Potential severe hypoglycemia events were further examined to exclude those where other conditions (i.e., insulinoma, severe liver disease, encephalitis, meningitis, and sepsis) were reported in the primary or secondary hospitalization diagnosis codes and may have caused the event. A list of the ICD codes that warranted exclusion is provided in the Supplementary Data. MI and stroke events that were recorded on the same day were included as MIs, given the elevated mortality risk in the first month post event for MIs compared with strokes.
Other major complications were defined from hospital and death records using ICD-9 and ICD-10 codes for the following: fatal and nonfatal MI, fatal or nonfatal stroke, heart failure, amputation, peripheral vascular disease (PVD), hyperglycemia, end-stage renal disease (ESRD), ischemic heart disease (IHD) and unstable angina, atrial fibrillation (AF), percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), and hypoglycemia. Full lists of the ICD-9 and ICD-10 codes are recorded in the Supplementary Data.
In addition to prior hospitalizations for comorbidities, additional risk factors at time of CVD event were considered. The last available measure prior to their CVD event was used in our analysis. Physicians and nurses in hospital clinics report to the NDR measures of HbA 1c , blood pressure, BMI, LDL cholesterol, HDL cholesterol, and total cholesterol at least annually via the Internet or via direct transfer of data from medical record databases. All HbA 1c values were converted to National Glycohemoglobin Standardization Program standard levels (10) . In addition to the current HbA 1c , a weighted average HbA 1c variable was also included to capture previous control of HbA 1c (metabolic memory) (11) . Estimated glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (12) . Formulae are provided in the Supplementary Data. Microalbuminuria was defined as urinary albumin excretion .20 mg/min but ,200 mg/min and macroalbuminuria as .200 mg/min in two out of three consecutive tests. Patients with macroalbuminuria were recorded as also having microalbuminuria.
Statistical Analysis
All analyses were undertaken using STATA (Stata Statistical Software, release 12.1; StataCorp, College Station, TX). Summary statistics were calculated at baseline (time at major CVD event) for patients and stratified by CVD event (MI or stroke) and prior hypoglycemic event. The Mann-Whitney test was used to test for statistical differences (at the 5% level) between patients with and without prior severe hypoglycemic events. Kaplan-Meier survival curves were estimated for patients stratified by prior severe hypoglycemic events. We conducted a logrank test for the equality of survivor functions for the Kaplan-Meier survival curves.
Time at risk was calculated from the time of the patients' complication to either their date of death or censoring by reaching the end of the study period (31 December 2012). As MI and stroke and the impact of different risk factors were associated with changing mortality risk over time (13) , a two-part model was used that included a logistic regression for survival within the first month, followed by a Cox model conditional on surviving 1 month.
Explanatory variables included in both models were type of complication (MI or stroke), age at complication, duration of diabetes, sex, smoking status, HbA 1c , BMI, systolic blood pressure, diastolic blood pressure, chronic kidney disease status based on estimated glomerular filtration rate, microalbuminuria and macroalbuminuria status, HDL, LDL, totalto-HDL cholesterol ratio, triglycerides, lipid medication status, clinic visits within the year prior to the CVD event, and prior hospitalization events: hypoglycemia, hyperglycemia, MI, stroke, heart failure, AF, amputation, PVD, ESRD, IHD/ unstable angina, PCI, and CABG.
The last known value for each clinical risk factor, prior to the cardiovascular complication, was used for analysis. Patients with missing values prior to their major CVD complication had their values imputed using chained equations (14, 15) , with five imputed data sets generated.
Initially, all explanatory variables were included and excluded if the variable was not statistically significant at a 5% level (P , 0.05) via stepwise backward elimination. We tested the proportional hazards assumption in the Cox model and did not find evidence to reject proportional hazards. A univariate analysis was also conducted using only prior hypoglycemic event in both logistic and Cox models to explore whether the impact of a prior hypoglycemic event may in part act through mediating other factors that impact on mortality.
For both logistic and Cox models, we tested the heterogeneity of the impact of a prior severe hypoglycemic event on all-cause mortality. One by one, we included and tested an interaction variable of severe hypoglycemia with 1) patients who had a stroke versus an MI, 2) patients experiencing their first CVD event versus patients who had prior CVD events, and 3) patients who experienced a hypoglycemic event within 5 years of the CVD event versus patients who experienced a hypoglycemic event .5 years before their CVD event.
In order to explore possible mechanisms through which severe hypoglycemia events might increase all-cause mortality, we also used the same sample to conduct another multivariate analysis (Cox model), which examined whether risk factors, in particular a history of severe hypoglycemia, predicted time to subsequent CVD events.
The logistic and Cox models were used to estimate the cumulative 5-year mortality risk after a cardiovascular event by using the baseline hazard from our sample. To calculate the first year of survival after a CVD event, we used the logistic model to calculate the probability of death for the first month after a CVD event and used the Cox model to calculate the probability of death for the remaining 11 months. Mortality each year thereafter was calculated using the Cox model only.
Our reference patient had mean baseline characteristics at the time of CVD event (and no prior complications). We estimated the impact on 5-year mortality for changes in important factors while holding all other things equal in a few hypothetical scenarios: patients with no complications, patients with prior hospitalization for hypoglycemia, patients with prior hospitalization for stroke, patients with prior hospitalization for heart failure, patients with macroalbuminuria, and patients with CKD stage 3 or above.
For determination of 95% CIs, 1,000 bootstrapped samples were used. Comparable estimates of mortality risk from the general population were obtained from Swedish life tables (16) and multiplied with the relative risk of mortality from a large type 1 diabetes population (17) to put any increased mortality after a cardiovascular event into perspective.
RESULTS
Summary Statistics
We identified 27,087 patients who had an NDR clinic visit between 1 January 2002 and 31 December 2010. We excluded 168 patients (0.62%), as they did not have any records of an insulin prescription for all years of the prescription data (2005-2011) and had not been recorded as dead. Of 7,509 (0.51%) patients, 38 had possible episodes of severe hypoglycemia, which were excluded, as they may have been caused by other conditions. There were 1,839 patients with an NDR clinic visit and a subsequent cardiovascular complication (MI or stroke) between 1 January 2002 and 31 December 2011. Of these patients, 16 (0.87%) had at least one hospital code that referred to them as having type 2 diabetes, of whom 10 (62.5%) had a prior hypoglycemic event, while 6 (37.5%) did not.
Baseline characteristics are summarized in Table 1 , along with the percentage missing for each variable. A total of 1,224 patients had an MI (of whom 24 had a stroke on the same day), and 615 After testing for significant differences using the Mann-Whitney test, patients with previous hypoglycemic hospitalizations were ;1.5 years older, had 2 additional years of diabetes duration, slightly lower BMI, and proportionately higher incidence of prior hospitalization events (stroke, hyperglycemia, PVD, amputation, and ESRD).
The Kaplan-Meier graphs in Fig. 1 depict a possible dose-response relationship between survival after a CVD event and previous episodes of severe hypoglycemia with those having had two or more events having higher mortality than those having had one prior event and those having had one prior event having higher mortality than those who have had no prior events. The log-rank test for Fig. 1 returned a x 2 value of 39.22 (P , 0.01) for mortality after a CVD event and previous episodes of severe hypoglycemia, which rejects the null hypothesis that the two curves are the same at the 1% significance level. Additional Kaplan-Meier graphs in the Supplementary Data show survival by CVD event type and that the possible dose-response relationship still exists when the sample is stratified by age and sex. Table 2 presents the significant variables and their estimated hazard ratios (HRs) for the logistic and Cox models when using backward stepwise regression (P , 0.05) and the univariate analysis Data) , the mortality increase associated with a prior severe hypoglycemic event was still significant, and the P values and SE are similar when compared with the backward stepwise regression. Similarly, when explanatory factors were included individually, the mortality increase associated with a prior severe hypoglycemic event was also still significant. When testing for possible heterogeneity of the relative impact of having had a prior severe hypoglycemic event for patients who had a stroke versus an MI for both logistic and Cox models, the null hypothesis of no difference could not be rejected at the 5% level (P = 0.853 logistic, P = 0.443 Cox). Similarly, we found no differences between patients with their first CVD event compared with subsequent CVD events (P = 0.842 logistic, P = 0.409 Cox) and patients who experienced a prior hypoglycemic event within 5 years of their CVD event compared with .5 years of their CVD event (P = 0.432 logistic, P = 0.346 Cox). The results of the Cox model, which examined whether the increase in all-cause mortality associated with prior severe hypoglycemia may have been driven by an increase in subsequent CVD events, are included in the Supplementary Data. Of those patients who survived their CVD event, 521 had a subsequent CVD event, and there was no evidence of a significant relationship between a history of severe hypoglycemia and subsequent CVD event (HR 0.95 [95% CI 0.72-1.25]).
The estimated 5-year cumulative mortality risk after a CVD event at age 60 Table 2 -Univariate analysis and manual backward stepwise logistic regression for death within 28 days from event using multiple imputed data sets (n = 1,839) and a Cox model for time to death after 28 days since first major cardiovascular event since the first clinic visit after 2002 (n = 1,613), conditional on 28-day survival (with imputation) years is presented in Fig. 2 
CONCLUSIONS
This is the first study that estimated risk equations for survival after major cardiovascular complications (MI and stroke) in patients with type 1 diabetes. We found evidence that prior severe hypoglycemia is associated with reduced survival after a major CVD event but no evidence that prior severe hypoglycemia is associated with an increased risk of a subsequent CVD event.
Compared with the general type 1 diabetic Swedish population, a major CVD complication increased 5-year mortality risk at age 60 years by .25% and 15% in patients with an MI and stroke, respectively. Patients with a history of a hypoglycemic event had an even higher mortality after a major CVD event, with approximately an additional 10% being dead at the 5-year mark. This risk was comparable with that in those with latestage kidney disease. This information is useful in determining the prognosis of patients after a major cardiovascular event and highlights the need to include this as a risk factor in simulation models (18) that are used to improve decision making (19) .
A strength of this study was the use of the NDR data, a large diabetes register that has been linked to hospital, prescription, and death data. The NDR includes a significant proportion of the type 1 diabetic population in Sweden and thus contains many more events compared with other large type 1 diabetes trials. The DCCT/ Epidemiology of Diabetes Interventions and Complications (EDIC) study identified 144 CVD events during the mean 17 years of follow-up in the trial (11) , while the EURODIAB Prospective Complications Study identified 176 patients with incident CVD (20) during 7 years of follow-up. In comparison, the NDR identified 1,839 CVD events over a maximum of 10 years of followup. Another key strength of the data is the wide range of prospectively collected clinical risk factors, which has enabled us to identify important risk factors and allows estimates of survival durations to be refined.
A recent systematic review of cardiac implications of hypoglycemia in patients with diabetes identified only one study of type 2 diabetic patients (ADVANCE) that could determine a clear association between prior severe hypoglycemia and increased risk of death from any cause (HR 2.69 [95% CI 1.97-3.67]) (21) . We have estimated a lower association in type 1 diabetes, with an HR of 1.79 (95% CI 1.37-2.35) in the first 28 days after a CVD event and an HR of 1.25 (95% CI 1.02-1.53) after 28 days post CVD event. Our other analysis suggests that having a prior hypoglycemic event Figure 2 -Estimated 5-year mortality risk after CVD events for 60-year-old patients with particular characteristics. Combined mortality from logistic and Cox regressions for baseline patient (without prior diabetes complications) and patients having had a prior hypoglycemic (hypo) event, a prior stroke event, a prior heart failure (HF) event, macroalbuminuria, CKD stage 3 or above, and the Swedish type 1 diabetic population for patients experiencing 1) an MI at age 60 years or 2) a stroke at age 60 years.
does not impact on having a subsequent CVD event. We can infer from this that it is more likely that a history of severe hypoglycemia modifies the response to a CVD event rather than increasing the likelihood of additional CVD events. This is the first study that has found some evidence of a dose-response relationship, where patients who experienced two or more severe hypoglycemic events had higher mortality after a cardiovascular event compared with those who experienced one severe hypoglycemic event. A lack of statistical power prevented us from investigating this further when we tried to stratify by number of prior severe hypoglycemic events in our regression models. There was no evidence of a dose-response relationship between repeated episodes of severe hypoglycemia and vascular outcomes or death in previous type 2 diabetes studies (5) . Our definition of a severe hypoglycemic event as a hospitalization was more restrictive than that used in the ADVANCE study (5), where severe hypoglycemia was selfreported and defined as hypoglycemia requiring help from another person.
A number of limitations of this study should be acknowledged. The models involve use of risk factor information that was collected in NDR clinics prior to the occurrence of the patient's CVD complication. Participation in the NDR is not compulsory and requires patients to make at least one clinic visit; hence, our analysis will tend to have excluded some of the older and sicker patients. We also analyzed the first cardiovascular complication after 2002dnot necessarily the first cardiovascular complication of a person's lifetimedthough we found no significant difference between the impacts of severe hypoglycemia for the first versus secondary events.
The NDR involves tracking of patients using their personal identification number; however, there are no follow-up data for patients who emigrate or information that would allow them to be censored, though those alive and without at least one insulin prescription filled per year after 2005 are excluded, which should exclude all those who migrated. As we only have data on severe hypoglycemic events from admitted hospitalizations, we are missing a number of nonadmitted events, which is a limitation from using a large observational data set. In the U.S., only 41% of nearly 14,000 emergency room visits for such events were admitted to hospital (22). An admission to hospital for severe hypoglycemic could potentially be an indicator of behavioral factors (such as poor nutrition) or health status, and thus their health outcomes may be worse than other patients with nonhospitalized hypoglycemic events. The equations also do not include any measure of socioeconomic status such as household income, which is a good predictor of mortality risk (23) . Finally, since mortality may be influenced by behavioral, health care system, and genetic factors that are not captured in our models, these results may not be directly generalizable to other populations without suitable calibration of the absolute risk.
This study could not account for hypoglycemia-associated mechanisms such as release of glucagon and catecholamines (epinephrine), enhanced platelet aggregation, cardiac autonomic neuropathy, or QTc interval changes, which lead to life-threatening cardiac arrhythmias that could explain the increased risk of mortality after a major CVD event in type 1 diabetic patients with histories of severe hypoglycemia (21) .
In summary, we have estimated equations for predicting mortality after a major CVD event in type 1 diabetic patients. The equations are based on age, sex, and commonly collected clinical information and thereby provide further stratification of a patient's prognosis after the occurrences of a life-threatening CVD event. This study highlights the prognostic importance of prior history of severe hypoglycemia on survival after a CVD event. More studies are required to determine whether prior severe hypoglycemia is itself a risk factor for mortality after a CVD event or a marker for another factor, such as cardiac autonomic neuropathy, which may be associated with elevated mortality (24) (25) (26) . E., and P.M.C. contributed to discussion and reviewed and edited the manuscript. T.W.C.L. and D.P. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
